Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:obinutuzumab
gptkb:cyclophosphamide |
| gptkbp:activities |
gptkb:weapon
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1960
|
| gptkbp:brand |
Leukeran
|
| gptkbp:class |
alkylating agents
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:composed_of |
reaction of nitrogen mustard with phenylacetic acid
|
| gptkbp:contraindication |
pregnancy
severe liver disease active infection |
| gptkbp:counseling_services |
avoid live vaccines during treatment
regular follow-up appointments are necessary report any signs of infection avoid pregnancy during treatment maintain hydration during treatment |
| gptkbp:developed_by |
gptkb:Ciba-Geigy
|
| gptkbp:discovered_by |
1950s
|
| gptkbp:dissolved |
soluble in water
soluble in alcohol |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
chlorambucil
|
| gptkbp:ingredients |
C14 H18 Cl2 N2 O2
|
| gptkbp:interacts_with |
live vaccines
other immunosuppressants |
| gptkbp:is_atype_of |
L01 A A02
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:is_used_for |
treatment of autoimmune diseases
treatment of chronic lymphocytic leukemia treatment of non-Hodgkin lymphoma treatment of Hodgkin's disease |
| gptkbp:level |
7.5
neutral |
| gptkbp:lifespan |
1-2 hours
|
| gptkbp:manager |
oral
|
| gptkbp:mass |
301.21 g/mol
|
| gptkbp:metabolism |
liver
phenylacetic acid derivative |
| gptkbp:related_to |
nitrogen mustard
|
| gptkbp:safety_features |
Category D
|
| gptkbp:side_effect |
nausea
vomiting diarrhea alopecia bone marrow suppression secondary malignancies |
| gptkbp:storage |
room temperature
|
| gptkbp:target_audience |
gptkb:Person
adults |
| gptkbp:type_of |
305-03-3
|